DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION 100 MCG
DEXMEDETOMIDINE (DEXMEDETOMIDINE HYDROCHLORIDE) : 100 MCG · DIN 02477327 · ACCORD HEALTHCARE INC
Health Canada status: MARKETED
What is DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION?
DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION 100 MCG contains DEXMEDETOMIDINE (DEXMEDETOMIDINE HYDROCHLORIDE) : 100 MCG. It is listed in the Health Canada Drug Product Database under DIN 02477327, held by ACCORD HEALTHCARE INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 29-Mar-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION used for?
Dexmedetomidine Hydrochloride for Injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting by continuous intravenous infusion. Dexmedetomidine Hydrochloride for Injection is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures by continuous intravenous infusion for Monitored Anesthesia Care (MAC) with an adequate nerve block and/or local infiltration; and Awake Fiberoptic Intubation (AFI) with adequate topical preparation of the upper airway with local lidocaine formulations.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02477327 |
|---|---|
| Brand name | DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION |
| Generic / active ingredient | DEXMEDETOMIDINE (DEXMEDETOMIDINE HYDROCHLORIDE) : 100 MCG |
| Manufacturer | ACCORD HEALTHCARE INC |
| Strength | 100 MCG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | N05CM18 DEXMEDETOMIDINE |
| AHFS class | 84:80.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Mar-2019 |
| Original market date | 2019-04-30 00:00:00 |
How is it stored and handled?
The reconstituted solution is stable for 25 hours at room temperature (15-30°C)
How is it supplied?
2 mL clear glass vials (200 mcg / 2 mL)
Is DEXMEDETOMIDINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by HIKMA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION
What can be used instead?
Other Canadian products sharing ATC code N05CM18 DEXMEDETOMIDINE. 9 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION | 100 MCG | SOLUTION | AURO PHARMA INC | MARKETED | DIN 02464381 |
| DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION | 100 MCG | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528886 |
| DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION, USP | 100 MCG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02513978 |
| DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION, USP | 100 MCG | SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02467976 |
| DEXMEDETOMIDINE HYDROCHLORIDE INJECTION | 200 MCG / 50 ML | SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02487365 |
| DEXMEDETOMIDINE HYDROCHLORIDE INJECTION | 4 MCG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02537109 |
| DEXMEDETOMIDINE HYDROCHLORIDE INJECTION | 400 MCG / 100 ML | SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02487373 |
| PRECEDEX | 4 MCG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02437147 |
| DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION | 100 MCG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02493314 |
| DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION USP | 100 MCG | SOLUTION | HIKMA CANADA LIMITED | APPROVED | DIN 02537095 |
Who else supplies DEXMEDETOMIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DEXMEDETOMIDINE appears in 45 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.